Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Roche synthesizes new JAK1 inhibitors

Aug. 12, 2011

CBio presents data from phase IIa XToll trial in rheumatoid arthritis

Aug. 8, 2011

Promising results reported on Vibex MTX in rheumatoid arthritis

Aug. 5, 2011

Enrollment begins in phase IIb/III study of masitinib in rheumatoid arthritis

Aug. 4, 2011

European Commission expands RoActemra label

Aug. 3, 2011

Femta Pharmaceuticals files IND with FDA for FM-101

Aug. 3, 2011

FDA approves subcutaneous formulation of Orencia

Aug. 1, 2011

Statin therapy may reduce cardiovascular risk in patients with SLE

Aug. 1, 2011

Janssen Biotech receives FDA complete response letter regarding Simponi

July 25, 2011

Phase III data presented on subcutaneous Actemra versus intravenous infusion

July 19, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...